Juan Antonio Reguera Márquez

Dr. Juan Antonio Reguera Márquez

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
JGJuan Francisco Gutiérrez-Bautista
Juan Francisco Gutiérrez-Bautista
ASAntonio Sampedro
Antonio Sampedro
EGEsther Gómez-Vicente
Esther Gómez-Vicente
JRJavier Rodríguez-Granger
Javier Rodríguez-Granger
JMJuan Antonio Reguera Márquez
Juan Antonio Reguera Márquez
MNMiguel Angel Lopez López Nevot
Miguel Angel Lopez López Nevot
The vaccines designed against the SARS-CoV-2 coronavirus are based on the spike (S) protein. Processing of the S protein by antigen-presenting cells (APC) and its subsequent presentation to T cells is an essential part of the development of a humoral response. HLA-class II alleles are considered immune response genes because their codified molecules, expressed on the surface of APCs (macrophages, dendritic, and B cells) present antigenic peptides to T cell via their T cell receptor (TCR). The HLA-class II genes are highly polymorphic, regulating what specific peptides induce follicular helper T cells (TFH) and promote B lymphocyte differentiation into plasma or memory B cells. This work hypothesizes that the presence of certain HLA-class II alleles could be associated with the intensity of the humoral response (amount, length) to the SARS-CoV2 mRNA 1273 vaccine. We have studied the relationship between the HLA-class II typing of 87 health workers and the level of antibodies produced 30 days after vaccination. We show a possible association between the HLA-DRB1* 07:01 allele and the HLA-DRB1*07:01~DQA1*02:01~DQB1*02:02 haplotype to a higher production of antibodies 30 days after the administration of the second dose of mRNA-1273.

11 March 2024 in Microorganisms
Verified
Journal Article
Open access
PDF file
JGJuan Francisco Gutiérrez-Bautista
Juan Francisco Gutiérrez-Bautista
MTMaría Tarriño
María Tarriño
AMAdrián Gonzalez Martínez
Adrián Gonzalez Martínez
MDMaría José Olivares Durán
María José Olivares Durán
FERNANDO COBOFERNANDO COBO
FERNANDO COBO
ASAntonio Sampedro
Antonio Sampedro
In this study, we have compared the detection of IgM and IgG against C. burnetii phase II of an enzyme-linked immunosorbent assay (ELISA) (Euroimmun) and a chemiluminescent immunoassay (CLIA) (VIRCLIA, Vircell). In addition, an indirect immunofluorescence assay (IFA) was used as a reference test. One hundred forty-eight sera were used for IgG evaluation, and eighty-eight for IgM. The sensitivity of ELISA and CLIA in detecting phase II IgM was excellent. On the other hand, the CLIA IgM showed better specificity than the ELISA IgM. As for phase II IgG, the specificity of ELISA and CLIA was similar, while the ELISA technique showed a higher sensitivity. In conclusion, the best system to detect phase II IgM antibodies against C. burnetii is the CLIA from Vircell, which is characterized by high sensitivity and specificity. For the detection of phase II IgG, the Euroimmun ELISA and Vircell CLIA assays are suitable for the determination of this marker in the laboratory, although the IgG ELISA has greater sensitivity.

30 March 2023 in Microorganisms
Verified
Journal Article
Open access
PDF file
SSSvetlana Sadyrbaeva-Dolgova
Svetlana Sadyrbaeva-Dolgova
MSMaría Del Mar Suárez Sánchez
María Del Mar Suárez Sánchez
JMJuan Antonio Reguera Márquez
Juan Antonio Reguera Márquez
Carmen Hidalgo-TenorioCarmen Hidalgo-Tenorio
Carmen Hidalgo-Tenorio
Nosocomial infections caused by non-fermenting Gram-negative bacteria are a real challenge for clinicians, especially concerning the accuracy of empirical treatment. This study aimed to describe the clinical characteristic, empirical antibiotic therapy, accuracy of these prescriptions for appropriate coverage and risk factor for clinical failure of bloodstream infections due to non-fermenting Gram-negative bacilli. This retrospective, observational cohort study was conducted between January 2016 and June 2022. Data were collected from the hospital’s electronic record. The statistic tests corresponding to each objective were applied. A multivariate logistic regression was performed. Among the total 120 patients included in the study, the median age was 63.7 years, and 79.2% were men. Considering the appropriate empirical treatment rate by species, inappropriate treatment for S. maltophilia was 72.4% (p = 0.088), for A. baumanii 67.6% and 45.6% for P. aeruginosa. Clinical success was achieved in 53.3%, and overall, 28-day mortality was 45.8%. ICU admission, sepsis or shock septic, age, previous antibiotic treatment and contact with healthcare facilities were independently associated with clinical failure. In conclusion, bloodstream infection produced by multidrug-resistant non-fermenting Gram-negative bacteria is a significant therapeutic management challenge for clinicians. The accuracy of empirical treatment is low due to the fact that it is not recommended to cover these microorganisms empirically, especially S. maltophilia and A. baumanii.

17 December 2024 in Microorganisms
Verified
Journal Article
Open access
PDF file
AMAdrián Gonzalez Martínez
Adrián Gonzalez Martínez
MFMaria Aguilera Franco
Maria Aguilera Franco
MTMaría Tarriño
María Tarriño
ARAna Romano
Ana Romano
JMJuan Antonio Reguera Márquez
Juan Antonio Reguera Márquez
JRJavier Rodríguez-Granger
Javier Rodríguez-Granger
The incidence of infections caused by the Mycobacterium avium complex (MAC) has risen significantly, posing diagnostic and therapeutic challenges. This study analyzed 134 clinical isolates of the Mycobacterium avium complex from southern Spain, performing in vitro antimicrobial susceptibility testing using a commercial microdilution technique to generate additional data, refine treatment strategies, and improve patient outcomes. Phenotypic susceptibility testing revealed clarithromycin and amikacin as the most effective antibiotics, with susceptibility rates exceeding 90%, while linezolid and moxifloxacin exhibited limited activity, with resistance rates of 49.3% and 41.8%. A comparative analysis between M. avium and M. intracellulare showed significant differences in resistance to amikacin and linezolid, with M. avium exhibiting higher resistance rates. Additionally, species-specific differences were observed in MIC distributions for ethionamide, ciprofloxacin, and streptomycin. Our data reveal regional variability in resistance patterns, particularly for moxifloxacin and linezolid, which exhibit differing resistance rates compared to studies from other regions. The significant MIC differences for several antibiotics between M. avium and M. intracellulare underscore the importance of species-level identification and the heterogeneity in resistance mechanisms within MAC.

10 April 2025 in Revista Española de Quimioterapia
Verified
Journal Article
Open access
FERNANDO COBOFERNANDO COBO
FERNANDO COBO
JRJavier Rodríguez-Granger
Javier Rodríguez-Granger
JNJosé Mª Navarro-Marí
José Mª Navarro-Marí
RCRafael Ceballos-Atienza
Rafael Ceballos-Atienza
ASAntonio Sampedro
Antonio Sampedro
JMJuan Antonio Reguera Márquez
Juan Antonio Reguera Márquez
Revista Española de Quimioterapia tiene un carácter multidisciplinar y está dirigida a todos aquellos profesionales involucrados en la epidemiología, diagnóstico, clínica y tratamiento de las enfermedades infecciosas. Fundada en 1988 por la Sociedad Española de Quimioterapia.

Verified
Journal Article
Open access
PDF file
JGJuan Francisco Gutiérrez-Bautista
Juan Francisco Gutiérrez-Bautista
ASAntonio Sampedro
Antonio Sampedro
LBLucía Ballesta
Lucía Ballesta
MAMaría Aguilera-Franco
María Aguilera-Franco
MOMaría José Olivares-Durán
María José Olivares-Durán
ASAntonio Sampedro
Antonio Sampedro
Leishmaniasis is an infectious disease caused by protozoa of the genus Leishmania, which is endemic in certain areas of Europe, such as southern Spain. The disease manifests in various clinical phenotypes, including visceral, cutaneous, mucosal, or asymptomatic leishmaniasis. This diversity in clinical outcomes may be influenced by the host immune response, with human leukocyte antigen (HLA) molecules playing a crucial role in determining susceptibility and progression of the infection. This study explores the association between specific HLA variants and Leishmania infantum infection. We recruited four cohorts: a control group, asymptomatic individuals, patients with symptomatic disease, and cohabitants of infected individuals. HLA typing was performed for all participants, followed by an association analysis with infection status and disease progression. Our findings indicate that the HLA-B*38 and HLA-C*03 alleles are associated with protection against L. infantum infection. These results contribute to a better understanding of the disease’s progression, offer potential for new therapeutic approaches such as vaccines, and expand the existing knowledge in the literature.